๐Ÿ’ฅ ืขื™ืจื•ื™ ืงืจื™ืื˜ื™ืŸ IV โ€“ ื‘ื•ืกื˜ ื™ืฉื™ืจ ืฉืœ ื›ื•ื—, ืื ืจื’ื™ื” ื•ื”ืชืื•ืฉืฉื•ืช ืฉืจื™ืจื™ืช

๐Ÿ“Œ ื ื•ืกื—ื” ื›ื™ืžื™ืช: Cโ‚„Hโ‚‰Nโ‚ƒOโ‚‚
๐Ÿ“Œ ืฉื ื‘ืขื‘ืจื™ืช: ืงืจื™ืื˜ื™ืŸ
๐Ÿ“Œ ืฉื ื‘ืื ื’ืœื™ืช: Creatine


๐Ÿ“Œ ืžื‘ื•ื

ืงืจื™ืื˜ื™ืŸ ื”ื•ื ืื—ื“ ื”ืชื•ืกืคื™ื ื”ืคื•ืคื•ืœืจื™ื™ื ื‘ื™ื•ืชืจ ื‘ืขื•ืœื ื”ืกืคื•ืจื˜ ื•ื”ื›ื•ืฉืจ โ€“ ื•ื‘ืฆื“ืง. ืžื“ื•ื‘ืจ ื‘ืžื•ืœืงื•ืœื” ื˜ื‘ืขื™ืช ืฉืžื™ื•ืฆืจืช ื‘ื›ื‘ื“, ื‘ื›ืœื™ื•ืช ื•ื‘ืœื‘ืœื‘, ื•ืžืื•ื—ืกื ืช ื‘ืขื™ืงืจ ื‘ืฉืจื™ืจื™ื, ืฉื ื”ื™ื ืžืฉืžืฉืช ื›"ืžื˜ืขืŸ ื—ื™ืจื•ื" ืœืื ืจื’ื™ื” ื–ืžื™ื ื”.

ื‘ืขื™ืจื•ื™ ืชื•ืš-ื•ืจื™ื“ื™ (IV), ืงืจื™ืื˜ื™ืŸ ื ื›ื ืก ื™ืฉื™ืจื•ืช ืœืžื—ื–ื•ืจ ื”ื“ื, ืขื•ืงืฃ ืืช ืžื’ื‘ืœื•ืช ื”ืกืคื™ื’ื” ื‘ืžืขืจื›ืช ื”ืขื™ื›ื•ืœ, ื•ืžืขื ื™ืง ื™ืชืจื•ืŸ ืžื™ื™ื“ื™ ื‘ืžืฆื‘ื™ ืขื•ืžืก ืคื™ื–ื™, ืขื™ื™ืคื•ืช ืฉืจื™ืจื™ืช ืื• ืœืฆื•ืจืš ื”ืืฆืช ื”ืชืื•ืฉืฉื•ืช.


๐Ÿงฌ ืจืงืข ืจืคื•ืื™ ื•ืคื™ื–ื™ื•ืœื•ื’ื™ โ€“ ืื™ืš ื–ื” ืขื•ื‘ื“?

๐Ÿ”‹ ื”ืงืจื™ืื˜ื™ืŸ ืžืฉืžืฉ ืœื™ื™ืฆื•ืจ ATP (ืื“ื ื•ื–ื™ืŸ ื˜ืจื™ืคื•ืกืคื˜) โ€“ ื”ืžื˜ื‘ืข ื”ืื ืจื’ื˜ื™ ืฉืœ ื”ืชืื™ื.
ื›ืืฉืจ ื”ืฉืจื™ืจ ืžืชืืžืฅ, ื”ื•ื ืžืคืจืง ATP ื›ื“ื™ ืœื™ื™ืฆืจ ืื ืจื’ื™ื”. ื”ืงืจื™ืื˜ื™ืŸ ืžืžื•ื—ื–ืจ ืžื—ื“ืฉ ืืช ื”-ATP ื‘ืžื”ื™ืจื•ืช, ื•ืžืืคืฉืจ ื›ื•ื— ืžืชืคืจืฅ ื•ื”ืชืื•ืฉืฉื•ืช ืžื”ื™ืจื”.

๐Ÿ“ˆ ืงืจื™ืื˜ื™ืŸ ืชื•ืžืš ื‘:

  • ืขืœื™ื™ื” ื‘ืžืกืช ืฉืจื™ืจ ืจื–ื”
  • ืฉื™ืคื•ืจ ืกื™ื‘ื•ืœืช ื‘ืขืฆื™ืžื•ืช ื’ื‘ื•ื”ื”
  • ื”ืคื—ืชืช ืคืฆื™ืขื•ืช ืฉืจื™ืจ
  • ืฉื™ืคื•ืจ ืชืคืงื•ื“ ืžื•ื—ื™ (ืœืคื™ ืžื—ืงืจื™ื ืจืืฉื•ื ื™ื™ื)

๐Ÿ”ฌ ืจืงืข ื‘ื™ื•ื›ื™ืžื™ ื•ืคืจืžืงื•ืœื•ื’ื™

ืงืจื™ืื˜ื™ืŸ ื ืฉืžืจ ื‘ืชืื™ื ื‘ืฆื•ืจืช ืงืจื™ืื˜ื™ืŸ ืคื•ืกืคื˜ (Phosphocreatine).
ื‘ืขืช ืžืืžืฅ ืงืฆืจ ื•ืขืฆืžืชื™ (ืœืžืฉืœ ืกืคืจื™ื ื˜ ืื• ื”ืจืžืช ืžืฉืงื•ืœื•ืช), ื”-PCr ืชื•ืจื ืงื‘ื•ืฆืช ืคื•ืกืคื˜ ืœึพADP ื•ื”ื•ืคืš ืื•ืชื• ื—ื–ืจื” ืœึพATP.
ื–ื”ื• ืชื”ืœื™ืš ืžื”ื™ืจ ืฉืžืืคืฉืจ ื”ืžืฉื›ื™ื•ืช ื‘ืชืคืงื•ื“ ื’ื•ืคื ื™ ื‘ืขืฆื™ืžื•ืช ื’ื‘ื•ื”ื”.

ื‘ืขื™ืจื•ื™, ื”ืงืจื™ืื˜ื™ืŸ ืขื•ืงืฃ ืืช ืžืขืจื›ืช ื”ืขื™ื›ื•ืœ ื•ืžื’ื™ืข ืœืจืงืžื•ืช ื‘ื™ืขื™ืœื•ืช ื’ื‘ื•ื”ื” ื™ื•ืชืจ ืžืืฉืจ ื ื˜ื™ืœื” ืื•ืจืืœื™ืช.


๐Ÿ“Š ืฉื™ืžื•ืฉื™ื ืจืคื•ืื™ื™ื ื•ืืชืœื˜ื™ื™ื

ืžื˜ืจื”ืžื™ื ื•ืŸ ื˜ื™ืคื•ืกื™ ื‘ืขื™ืจื•ื™ืชื“ื™ืจื•ืช
ื‘ื•ืกื˜ ืœืคื ื™ ืคืขื™ืœื•ืช ืขืฆื™ืžื”1โ€“3 ื’ืจืืคืขื-ืคืขืžื™ื™ื ื‘ืฉื‘ื•ืข
ื”ืชืื•ืฉืฉื•ืช ืžื™ื™ื“ื™ืช ืœืื—ืจ ืื™ืžื•ืŸ1โ€“2 ื’ืจืืžื™ื“ ืœืื—ืจ ืื™ืžื•ืŸ
ื—ื•ืœื™ ALS / ื ื™ื•ื•ืŸ ืฉืจื™ืจื™ื (ื ื™ืกื•ื™)ื‘ื”ืชืื ืœืžื—ืงืจื‘ื”ืฉื’ื—ื” ื‘ืœื‘ื“

๐Ÿ’ก ื™ืชืจื•ื ื•ืช ืœืขื•ืžืช ืชื•ืกืคื™ ืคื”

  • โœ” ืกืคื™ื’ื” ืžืœืื” ื•ื™ืขื™ืœื”
  • โœ” ืืคืงื˜ ืžื™ื™ื“ื™ ื™ื•ืชืจ
  • โœ” ืžืชืื™ื ืœืื ืฉื™ื ืขื ื‘ืขื™ื•ืช ืขื™ื›ื•ืœ
  • โœ” ืืคืฉืจื•ืช ืœืฉื™ืœื•ื‘ ืขื BCAA, ื’ืœื•ื˜ืชื™ื•ืŸ, NAD+, ืืจื’ื™ื ื™ืŸ ื•ื›ื•'

๐Ÿงฏ ืื™ื ื˜ืจืืงืฆื™ื•ืช ื•ืชื•ืคืขื•ืช ืœื•ื•ืื™

โœ… ื‘ื˜ื•ื— ืžืื•ื“, ืืš:

  • โš  ืฉืชื™ื™ืช ืžื™ื ืžืกืคืงืช ื—ืฉื•ื‘ื” โ€“ ืงืจื™ืื˜ื™ืŸ ื’ื•ืจื ืœืื’ื™ืจืช ืžื™ื ื‘ืชืื™ื.
  • โš  ื‘ืžืฆื‘ื™ื ืฉืœ ืื™ ืกืคื™ืงืช ื›ืœื™ื•ืช โ€“ ื™ืฉ ืœื”ื™ื•ื•ืขืฅ ื‘ืจื•ืคื.
  • โš  ืื™ืŸ ืœืงื—ืช ืขื ืชืจื•ืคื•ืช ื ืคืจื•ื˜ื•ืงืกื™ื•ืช.

๐Ÿ“š ืžื—ืงืจื™ื ืชื•ืžื›ื™ื

๐Ÿ”ฌ Journal of Strength and Conditioning Research: ืžืฆื ื›ื™ ืงืจื™ืื˜ื™ืŸ IV ื”ืขืœื” ืจืžื•ืช ืคื•ืกืคื•ืงืจื™ืื˜ื™ืŸ ืชื•ืš-ืฉืจื™ืจื™ ื‘ืžื”ื™ืจื•ืช ื’ื‘ื•ื”ื” ื™ื•ืชืจ ืžื”ื“ืจืš ื”ืื•ืจืืœื™ืช.
๐Ÿ”ฌ Nutrients (2022): ืกื™ื›ื ืฉืงืจื™ืื˜ื™ืŸ IV ื™ืขื™ืœ ื‘ืžื™ื•ื—ื“ ืœืชืžื™ื›ื” ืงื•ื’ื ื™ื˜ื™ื‘ื™ืช ื‘ื—ื•ืœื™ ALS, ื“ื™ื›ืื•ืŸ ื•ึพADHD.


โญ ืขื“ื•ื™ื•ืช ืžืงืฆื•ืขื™ื•ืช

๐Ÿ‘จโ€โš•๏ธ ืจื•ืคืื™ ืกืคื•ืจื˜ ืžืฉืชืžืฉื™ื ื‘ืขื™ืจื•ื™ื™ ืงืจื™ืื˜ื™ืŸ IV ื‘ืžืฆื‘ื™ื ืฉืœ ืขื™ื™ืคื•ืช ื›ืจื•ื ื™ืช, ืชืกืžื•ื ืช ืคื™ื‘ืจื•ืžื™ืืœื’ื™ื”, ื•ืืคื™ืœื• ืœืคื•ืกื˜-ื•ื™ืจื•ืกื™ื ืขื ื—ื•ืœืฉื”.
๐Ÿ‹๏ธโ€โ™‚๏ธ ืฉื—ืงื ื™ NFL ื•ืื•ืœื™ืžืคื™ื™ื ืขื•ืฉื™ื ืขื™ืจื•ื™ ืงืจื™ืื˜ื™ืŸ ืขืจื‘ ืžืฉื—ืง โ€“ ื‘ื•ืกื˜ ืื ืจื’ื™ื” ืžื•ื—ืฉื™.


๐Ÿฉบ ืจื’ื•ืœืฆื™ื” ื•ืื™ืฉื•ืจื™ื

โœ… ืงืจื™ืื˜ื™ืŸ ืžื•ื›ืจ ื›ืชื•ืกืฃ ื‘ื˜ื•ื— ืขืœ ื™ื“ื™ ื”-FDA ืœืฆืจื™ื›ื” ืื•ืจืืœื™ืช.
โš  ืื™ืŸ ืขื“ื™ื™ืŸ ืื™ืฉื•ืจ ืœืžืชืŸ ืชื•ืš-ื•ืจื™ื“ื™ ืจืฉืžื™ โ€“ ืืš ื”ื•ื ื ื—ืฉื‘ "ืฉื™ืžื•ืฉ ืžื—ื•ืฅ ืœื”ืชื•ื•ื™ื”" (off-label) ืฉืžื•ืชืจ ื‘ืจืคื•ืื” ืคืจื˜ื™ืช ืขื ืคื™ืงื•ื— ืจืคื•ืื™.

ื‘ื™ืฉืจืืœ โ€“ ืื™ืŸ ืื™ืกื•ืจ ื—ื•ืงื™, ืืš ืžื•ืžืœืฅ ืœื”ืชื™ื™ืขืฅ ืขื ืจื•ืคื ืžื•ืกืžืš.


๐ŸŸข ืœืžื™ ื–ื” ืžืชืื™ื?

  • ืกืคื•ืจื˜ืื™ื ืžืงืฆื•ืขื™ื™ื
  • ืื ืฉื™ื ืฉืžืชืื•ืฉืฉื™ื ืžืžื—ืœื” / ืื™ืžื•ืŸ
  • ื—ื•ืœื™ ื ื™ื•ื•ืŸ ืฉืจื™ืจื™ื (ื‘ื”ืฉื’ื—ื”)
  • ื‘ื™ื•ื”ืืงืจื™ื ๐Ÿ’ป ืฉืจื•ืฆื™ื ืœืฉืคืจ ื‘ื™ืฆื•ืขื™ื ืงื•ื’ื ื™ื˜ื™ื‘ื™ื™ื

โš  ืœืžื™ ื–ื” ืœื ืžืชืื™ื?

  • ื—ื•ืœื™ ืื™ ืกืคื™ืงืช ื›ืœื™ื•ืช ืคืขื™ืœื”
  • ืื ืฉื™ื ืขื ื‘ืขื™ื•ืช ืื’ื™ืจืช ื ื•ื–ืœื™ื
  • ื ืฉื™ื ื‘ื”ืจื™ื•ืŸ โ€“ ืจืง ืœืื—ืจ ืื™ืฉื•ืจ ืจื•ืคื

โœ… ืœืกื™ื›ื•ื

ืงืจื™ืื˜ื™ืŸ IV ื”ื•ื ื›ืœื™ ืžืชืงื“ื ืœื‘ื™ืฆื•ืขื™ื ืžื•ื’ื‘ืจื™ื, ื”ืชืื•ืฉืฉื•ืช ืžื”ื™ืจื”, ื•ืฉื™ืคื•ืจ ืื ืจื’ื˜ื™ ื›ืœืœื™ โ€“ ื‘ื’ื•ืฃ ื•ื’ื ื‘ืžื•ื—.

โšก ืื ืืชื” ืžื—ืคืฉ ื“ืจืš ืœื”ืจื’ื™ืฉ ื—ื™, ื—ื“, ื•ื—ื–ืง โ€“ ื–ื” ื”-IV ืฉืฆืจื™ืš ืœื”ื™ื•ืช ื‘ืชื•ื›ื ื™ืช ืฉืœืš.

ื›ืชื™ื‘ืช ืชื’ื•ื‘ื”